Sonablate, a medical technology company focused on non-invasive prostate cancer treatment using high-intensity focused ultrasound (HIFU) , today announced the appointment of Brad Saar, former ...

Add Yahoo as a preferred source to see more of our stories on Google. Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug ...

MRI-guided transurethral ultrasound ablation associated with less blood loss, shorter stays, and less pain than robotic prostatectomy ...

ATLANTA, GA / ACCESS Newswire / April 17, 2026 / Advanced Urology , a leading provider of comprehensive urologic care in the ...

A new randomized clinical trial found that men with localized, intermediate-risk prostate cancer recovered faster and ...

Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...

High-intensity focused ultrasound (HIFU) is a noninvasive way to destroy tissue or stop it from working. It was approved by the U.S. Food and Drug Administration for prostate ablation in 2015, but the ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

A recent randomized clinical trial has found that men with localized, intermediate-risk prostate cancer recovered faster and experienced less short-term impact on their daily lives when treated with ...